NCT00099437 2026-03-18
CONFIRM
AstraZeneca
Phase 3 Active not recruiting
Clinical Trials
263 trialsNCT00310180 2026-03-18
TAILORx
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT01272037 2026-03-18
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT05654623 2026-03-18
VERITAC-2
Pfizer
Phase 3 Active not recruiting
NCT02445391 2026-03-13
Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy
Eastern Cooperative Oncology Group
Phase 3 Active not recruiting
NCT01349322 2026-03-05
Higher Per Daily Treatment-Dose Radiation Therapy or Standard Per Daily Treatment Radiation Therapy in Treating Patients With Early-Stage Breast Cancer That Was Removed by Surgery
Radiation Therapy Oncology Group
Phase 3 Active not recruiting
NCT04494425 2026-03-04
DB-06
AstraZeneca
Phase 3 Active not recruiting
NCT00433511 2026-03-03
Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT03523585 2026-02-27
DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]
Daiichi Sankyo
Phase 3 Completed
NCT03414970 2026-02-24
Hypofractionated Radiation Therapy After Mastectomy in Preventing Recurrence in Patients With Stage IIa-IIIa Breast Cancer
Alliance for Clinical Trials in Oncology
Phase 3 Active not recruiting
NCT04024462 2026-02-20
A Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Chinese Participants With HER2-Positive Early Breast Cancer
Hoffmann-La Roche
Phase 3 Completed
NCT02032823 2026-02-17
OlympiA
AstraZeneca
Phase 3 Active not recruiting
NCT02000622 2026-02-13
OlympiAD
AstraZeneca
Phase 3 Completed
NCT04739761 2026-02-11
DESTINY-B12
AstraZeneca
Phase 3 Active not recruiting
NCT01674140 2026-02-10
e3
SWOG Cancer Research Network
Phase 3 Active not recruiting
NCT05415215 2026-02-10
ProHer
Hoffmann-La Roche
Phase 3 Completed
NCT00066690 2026-02-06
SOFT
ETOP IBCSG Partners Foundation
Phase 3 Completed
NCT02763566 2026-02-05
MONARCH plus
Eli Lilly and Company
Phase 3 Active not recruiting
NCT05104866 2026-02-04
A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)
AstraZeneca
Phase 3 Active not recruiting
NCT02246621 2026-02-03
MONARCH 3
Eli Lilly and Company
Phase 3 Active not recruiting
NCT05169567 2026-01-16
postMONARCH
Eli Lilly and Company
Phase 3 Active not recruiting
NCT03199885 2025-12-30
Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer
National Cancer Institute (NCI)
Phase 3 Completed
NCT04148911 2025-12-26
EL1SSAR
Hoffmann-La Roche
Phase 3 Completed
NCT02115282 2025-12-18
Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT03975647 2025-12-10
A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer
Seagen Inc.
Phase 3 Active not recruiting
NCT01358877 2025-11-28
APHINITY
Hoffmann-La Roche
Phase 3 Completed
NCT03371017 2025-11-12
IMpassion132
Hoffmann-La Roche
Phase 3 Completed
NCT02297438 2025-10-27
A Study Of Palbociclib (PD-0332991) + Letrozole VS. Placebo+ Letrozole For 1st Line Treatment Of Asian Postmenopausal Women With ER+/HER2- Advanced Breast Cancer [PALOMA-4]
Pfizer
Phase 3 Completed
NCT02107703 2025-10-21
MONARCH 2
Eli Lilly and Company
Phase 3 Active not recruiting
NCT03529110 2025-10-21
DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03]
Daiichi Sankyo
Phase 3 Active not recruiting
NCT03734029 2025-10-06
Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]
Daiichi Sankyo
Phase 3 Active not recruiting
NCT03367572 2025-09-25
Treatment of Refractory Nausea and Vomiting in Patients With Breast Cancer
University of Rochester
Phase 3 Completed
NCT03778931 2025-09-15
EMERALD
Stemline Therapeutics, Inc.
Phase 3 Completed
NCT04478266 2025-09-11
AMEERA-5
Sanofi
Phase 3 Terminated
NCT04815083 2025-09-03
Fluorescence Imaging of Carcinoma During Breast Conserving Surgery
SBI ALApharma Canada, Inc.
Phase 3 Terminated
NCT00770809 2025-08-15
Paclitaxel and Trastuzumab With or Without Lapatinib in Treating Patients With Stage II or Stage III Breast Cancer That Can Be Removed by Surgery
National Cancer Institute (NCI)
Phase 3 Completed
NCT04740918 2025-08-08
KATE3
Hoffmann-La Roche
Phase 3 Terminated
NCT00070564 2025-07-31
S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer
SWOG Cancer Research Network
Phase 3 Active not recruiting
NCT01772472 2025-07-22
A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE)
Hoffmann-La Roche
Phase 3 Completed
NCT04915755 2025-07-16
ZEST
GlaxoSmithKline
Phase 3 Active not recruiting
NCT04752332 2025-07-15
eMonarcHER
Eli Lilly and Company
Phase 3 Terminated
NCT01275677 2025-07-14
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
National Cancer Institute (NCI)
Phase 3 Completed
NCT04975308 2025-07-11
EMBER-3
Eli Lilly and Company
Phase 3 Active not recruiting
NCT00769379 2025-06-12
Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy
National Cancer Institute (NCI)
Phase 3 Completed
NCT04588246 2025-06-06
Comparing Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to Stereotactic Radiosurgery in Patients With Cancer That Has Spread to the Brain and Come Back in Other Areas of the Brain After Earlier Stereotactic Radiosurgery
NRG Oncology
Phase 3 Terminated
NCT00253422 2025-06-04
SoFEA
Institute of Cancer Research, United Kingdom
Phase 3 Completed
NCT00601900 2025-05-23
Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage IIIB or Stage IV Breast Cancer
National Cancer Institute (NCI)
Phase 3 Completed
NCT04989504 2025-04-29
Testing the Application of Mepitel Film During Radiation Therapy to Reduce Radiation Related Redness and Peeling in Breast Cancer Patients Following Mastectomy
Alliance for Clinical Trials in Oncology
Phase 3 Active not recruiting
NCT00265759 2025-04-23
Exemestane, Letrozole, or Anastrozole in Treating Postmenopausal Women Who Are Undergoing Surgery for Stage II or Stage III Breast Cancer
Alliance for Clinical Trials in Oncology
Phase 3 Completed
NCT03155997 2025-04-20
monarchE
Eli Lilly and Company
Phase 3 Active not recruiting